Staphylococcus aureus MAPS Vaccine Merging B and T Cell Antigens
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine candidates for Staphylococcus aureus have failed in clinical trials, despite showing efficacy in animal models, highlighting a need for improved immunogenic compositions that can effectively prevent infection and colonization.
Innovation Solution
The development of an improved immunogenic Multiple Antigen Presenting System (MAPS) comprising a biotinylated immunogenic polysaccharide and specific Staphylococcus aureus antigens, such as those from Group A (SA1739, SA1720, SA1890, SA0103, SA0377, SA0693, and SA2105), fused to a biotin-binding protein, to elicit a synergistic humoral and cellular immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional polysaccharide-based vaccines are used, then humoral immune response is elicited, but clinical efficacy is insufficient and infection prevention fails
Solution Approach 1:
The patent combines multiple S. aureus antigens (including B-cell antigens SA1739, SA1720, SA1890 and T-cell antigens SA0103, SA0377, SA0693, SA2105) with a common carrier protein to create a multiple antigen presenting system (MAPS). This merging of multiple antigens onto a single platform enables simultaneous presentation of diverse immunogenic epitopes, resolving the contradiction by providing comprehensive antigenic coverage that conventional single-antigen vaccines cannot achieve, thereby improving vaccine efficacy against S. aureus infections
Solution Approach 2:
The common carrier protein serves multiple functions: it acts as a structural scaffold for displaying multiple S. aureus antigens, provides immunogenicity itself to stimulate both humoral and cellular responses, and facilitates T-cell help for B-cell activation. This multi-functionality allows a single vaccine formulation to elicit comprehensive immune responses including antibody production and T-cell mediated protection, addressing the limitation of conventional vaccines that target only specific aspects of immunity
2Reliability
If multiple S. aureus antigens are combined in a vaccine, then comprehensive immune response is achieved, but vaccine formulation complexity increases
Solution Approach 1:
The patent merges 8 different S. aureus antigens (SA1739, SA1720, SA1890, SA0103, SA0377, SA0693, SA2105 and additional antigens) onto a single common carrier protein platform. This merging strategy achieves comprehensive immune response coverage while managing formulation complexity by using one standardized carrier protein that can display multiple antigens in a controlled manner, rather than requiring separate delivery systems for each antigen
Solution Approach 2:
The vaccine composition is segmented into distinct functional modules: the common carrier protein serves as the structural and immunogenic core, while multiple S. aureus antigens are displayed as separate epitopic elements on the carrier surface. This segmentation allows for modular assembly and standardized production while ensuring that each antigen component contributes specifically to the comprehensive immune response
3Reliability
If T-cell and B-cell antigens are included, then synergistic immune protection is achieved, but manufacturing precision requirements increase
Solution Approach 1:
The patent merges T-cell antigens (SA0103, SA0377, SA0693, SA2105) and B-cell antigens (SA1739, SA1720, SA1890) onto a single common carrier protein that presents both antigen types with appropriate spatial arrangement. This merging enables synergistic immune protection by ensuring simultaneous presentation of antigens that stimulate both T-cell and B-cell responses, while the standardized carrier protein platform helps manage manufacturing precision requirements through a consistent presentation framework
Solution Approach 2:
The common carrier protein provides local quality differentiation by presenting T-cell and B-cell antigens in specific spatial arrangements on its surface. This local quality approach ensures that T-cell and B-cell antigens are displayed with appropriate orientation and accessibility to their respective immune cells, facilitating precise immunological interactions while maintaining manufacturing consistency through a standardized carrier structure
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The SA-MAPS composition generates a robust immune response, including antibody and B-cell responses, as well as T-cell responses such as Th1, Th2, Th17, and Th22, providing long-lasting protection against Staphylococcus aureus infections.
Implementation Method 1
comprising a biotinylated immunogenic polysaccharide and Staphylococcus aureus antigens, such as those from Group A (SA1739, SA1720, SA1890, SA0103, SA0377, SA0693, and SA2105), fused to a biotin-binding protein
Data Source
AI summary
The present embodiments provide for an S. aureus (SA). Multiple Antigen Presenting System (MAPS) immunogenic composition comprising an immunogenic polysaccharide which induces a B-cell and T-cell immune response, where at least one S. aureus (SA) peptide or polypeptide antigen is associated to the immunogenic polysaccharide by complementary affinity molecules. The present SA-MAPS immunogenic composition herein generates an immune response in a subject, preferably an antibody response and a B-cell and/or T-cell response, and can comprise at least one B-cell SA antigen and at least one T-cell SA antigen, and can elicit both humoral and cellular immune responses to the immunogenic polysaccharide and one, or multiple SA antigens at the same time.